Literature DB >> 3801787

Cytostatic action of two nitrosoureas derived from cysteamine.

C Bourut, E Chenu, D Godenèche, J C Madelmont, R Maral, G Mathé, G Meyniel.   

Abstract

2-Chloroethyl nitrosocarbamoylcystamine or ICIG-1325 (CNCC) is a lipid-soluble isomeric mixture of nitrosoureas. Its dose-effect relationship on L1210 leukaemia is characterized by a large maximally efficient dose-range (MEDR), greater than that of other nitrosoureas. CNCC also demonstrated significant therapeutic activity on intracerebrally (i.c.) transplanted L1210 leukaemia and on six transplanted solid tumours, TM2 mammary carcinoma, M555 ovarian carcinoma, B16 melanoma, glioma 26, 3LL, Lewis lung carcinoma and colon 26 carcinoma. It was inactive on fibrosarcoma ICIG-Ci4. Its antitumour activity spectrum is wider than that of the related compounds 2-[3-(2-chloroethyl) 3-nitrosoureido]D-glucopyranose (CZT), (chloro-2-ethyl)-1(ribofuranosyl-isopropylidene-2'-3' paranitrobenzoate-5')-3 nitrosourea (RFCNU), and (chloro-2-ethyl)-1 (ribopyranosyl triacetate-2'-3'-4')-3 nitrosourea (RPCNU). A study of its metabolic disposition in animals has shown that CNCC undergoes extensive first-pass metabolism leading to the formation of four main plasma metabolites. These metabolites are water-soluble nitrosoureas that arose from the bioreduction of the disulphide bridge followed by the methylation and the oxidation of the thiol groups. Experimental screening was performed with these chemically synthesized metabolites. Both N'-(2-chloroethyl)-N-[2-(methylsulphinyl)ethyl]-N'-nitrosourea (CMSOEN2) and N'-(2-chloroethyl)-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea (CMSO2EN2) are very active on L1210 leukaemia grafted intraperitoneally (i.p.) and i.c., L40 leukaemia, B16 melanoma, glioma 26 and Lewis lung carcinoma. Their effectiveness is better than that of the parent compound CNCC. In addition,the percentage of mice cured after CMSOEN2 or CMSO2EN2 treatment is increased especially on B16 melanoma and glioma 26. 6 Haematological toxicity of both active metabolites is lower than that of CNCC, particularly on platelets which is the main toxicity location due to nitrosoureas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801787      PMCID: PMC1917164          DOI: 10.1111/j.1476-5381.1986.tb11154.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin.

Authors:  T P Johnston; G S McCaleb; J A Montgomery
Journal:  J Med Chem       Date:  1975-01       Impact factor: 7.446

Review 2.  An overview of the status of the nitrosoureas in other tumors.

Authors:  S K Carter
Journal:  Cancer Chemother Rep 3       Date:  1973-05

3.  3-(Tetraacetyl glucopyranos-2-yl)-1-(2-chloroethyl)-1-nitrosourea, an antitumor agent with modified bone marrow toxicity.

Authors:  P S Schein; M G McMenamin; T Anderson
Journal:  Cancer Res       Date:  1973-09       Impact factor: 12.701

Review 4.  Methyl-CCNU inclinical cancer therapy.

Authors:  T H Wasserman; M Slavik; S K Carter
Journal:  Cancer Treat Rev       Date:  1974-12       Impact factor: 12.111

5.  The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally?

Authors:  G Mathé; C Jasmin
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU.

Authors:  G Mathe; P Schein; J S MacDonald; J L Imbach; J L Misset; F De Vassal; P Ribaud; B Serrou; J Gouveia; M Musset; D Machover; L Schwarzenberg; C Jasmin; R de Jager
Journal:  Eur J Cancer Clin Oncol       Date:  1982-08

7.  [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)].

Authors:  G Mathé; P S Schein; F De Vassal; B Serrou; J L Imbach
Journal:  Sem Hop       Date:  1982-09-16

8.  Flow cytofluorometric analysis of the effects of new nitrosourea derivatives on proliferation of EMT 6 tumor cells "in vitro".

Authors:  M N Vlaeminck; M Collyn-d'Hooghe; P Cappelaere; G Biserte; J Oiry; J L Montero; J L Imbach
Journal:  Biomedicine       Date:  1981-03

9.  New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor results.

Authors:  J C Madelmont; D Godeneche; D Parry; J Duprat; J L Chabard; R Plagne; G Mathe; G Meyniel
Journal:  J Med Chem       Date:  1985-09       Impact factor: 7.446

10.  In vivo study of acute hematotoxicity of three nitrosoureas, chlorozotocin (chloro-2-ethyl)-ribofuranosyl-3-nitrosourea, and (chloro-2-ethyl)-1-ribopyranosyl-3-nitrosourea.

Authors:  K J Mori; C Jasmin; M Hayat; J S MacDonald; G Mathé
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

View more
  2 in total

1.  Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.

Authors:  H Roche; H Cure; A Adenis; P Fargeot; C Terret; M A Lentz; J C Madelmont; P Fumoleau; A Hanausk; P Chollet
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

2.  Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma.

Authors:  E Debiton; C Cussac-Buchdhal; E Mounetou; M Rapp; J M Dupuy; J C Maurizis; A Veyre; J C Madelmont
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.